- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Path Towards a Tailored Clinical Biosimilar Development ; volume:34 ; number:3 ; day:7 ; month:4 ; year:2020 ; pages:297-306 ; date:6.2020
BioDrugs ; 34, Heft 3 (7.4.2020), 297-306, 6.2020
- Creator
-
Schiestl, Martin
Ranganna, Gopinath
Watson, Keith
Jung, Byoungin
Roth, Karsten
Capsius, Björn
Trieb, Michael
Bias, Peter
Maréchal-Jamil, Julie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-020-00422-1
- URN
-
urn:nbn:de:101:1-2020071622132042769621
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
11.08.2025, 3:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schiestl, Martin
- Ranganna, Gopinath
- Watson, Keith
- Jung, Byoungin
- Roth, Karsten
- Capsius, Björn
- Trieb, Michael
- Bias, Peter
- Maréchal-Jamil, Julie
- SpringerLink (Online service)
Other Objects (12)
Statistical topics in clinical biosimilar development
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Europe's path towards innovation and technology
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Graphene nanofibers: A modern approach towards tailored gypsum composites
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
Optimal Robot Path Planning for Multiple Goals Visiting Based on Tailored Genetic Algorithm
MYL-1402O: A Bevacizumab Biosimilar
Statistical topics in clinical biosimilar development
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Europe's path towards innovation and technology
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Graphene nanofibers: A modern approach towards tailored gypsum composites
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
Optimal Robot Path Planning for Multiple Goals Visiting Based on Tailored Genetic Algorithm
MYL-1402O: A Bevacizumab Biosimilar
Statistical topics in clinical biosimilar development
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
Europe's path towards innovation and technology
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Graphene nanofibers: A modern approach towards tailored gypsum composites
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
Optimal Robot Path Planning for Multiple Goals Visiting Based on Tailored Genetic Algorithm